ERBB3 and colorectal carcinoma: Consistently, AMT-562 (5–10 mg/kg) demonstrated improved antitumor activity over HER3-DXd in several HER3-low xenograft models (5–10 mg/kg) and durable responses in HER3-Dxd insensitive CRC PDXs.